Radiotherapy system receives CE mark extension

Article

A proprietary radiotherapy system (IRay, Oraya Therapeutics) used to treat exudative age-related macular degeneration (AMD) now also may be used to treat choroidal metastases following a CE mark extension.

A proprietary radiotherapy system (IRay, Oraya Therapeutics) used to treat exudative age-related macular degeneration (AMD) now also may be used to treat choroidal metastases following a CE mark extension.

“While Oraya’s primary focus remains on treating wet AMD, we continue to identify and evaluate other uses of the technology that may benefit patients and clinicians,” Oraya CEO Jim Taylor said in a statement.

More in this issue: Visual function linked to preBCVA in AMD cataract patients

The system delivers radiation to the back of the eye via a robotically positioned low-energy X-ray source. According to Oraya, the 15- to 20-minute non-invasive procedure is an alternative to surgery and related multiple treatment sessions.

The proprietary radiotherapy system received CE certification for the treatment of exudative AMD in March 2010, and the company actively began commercializing it in 2014. The radiotherapy is now available at 11 treatment centers in Germany, the UK and Switzerland, and plans are under way that would enable it to be available at an additional 11 centers.

 

In December 2014, Carl Zeiss Meditec AG and Oraya entered into a collaboration through which Carl Zeiss Meditec will fund Oraya’s growth strategy, particularly its expansion in Europe, for up to 2 years. In the US the system is considered an investigational device and is not available for purchase.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.